Clearmind Expands U.S. IP Portfolio with Psychedelic Combinations
Event summary
- Clearmind published three U.S. patent applications covering LSD, ketamine, and ibogaine combinations with N-acylethanolamines.
- The applications target mental health disorders, pain, and substance use disorders.
- This expands Clearmind's collaboration with NeuroThera Labs, which integrates PEA technology into psychedelic therapeutics.
- Clearmind's IP portfolio now includes 19 patent families with 32 granted patents.
- The company aims to reduce therapeutic doses while maintaining efficacy and improving tolerability.
The big picture
Clearmind's latest patent filings reinforce its strategy of combining psychedelics with non-hallucinogenic compounds to enhance therapeutic potential. This aligns with broader industry trends toward safer, more scalable mental health treatments. The company's expanding IP portfolio positions it as a key player in the neuroplastogen space, though success will depend on regulatory approvals and clinical validation.
What we're watching
- Regulatory Momentum
- How growing clinical and regulatory interest in LSD, ketamine, and ibogaine will impact Clearmind's patent strategy.
- Combination Efficacy
- Whether Clearmind's lower-dose approach with N-acylethanolamines can deliver proven therapeutic benefits.
- IP Expansion
- The pace at which Clearmind will file additional patents to strengthen its neuroplastogen portfolio.